Share This Page
Drug Price Trends for QC MUCUS RLF MAX
✉ Email this page to a colleague
Average Pharmacy Cost for QC MUCUS RLF MAX
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QC MUCUS RLF MAX 400-20 MG/20 ML | 83324-0026-06 | 0.02038 | ML | 2024-12-18 |
| QC MUCUS RLF MAX 400-20 MG/20 ML | 83324-0026-06 | 0.02027 | ML | 2024-12-04 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
QC MUCUS RLF MAX Market Analysis and Financial Projection
Market Analysis and Price Projections for QC MUCUS RELIEF ER
Introduction to QC MUCUS RELIEF ER
QC MUCUS RELIEF ER, containing the active ingredient guaifenesin, is an extended-release tablet designed to provide relief from chest congestion and mucus. Guaifenesin is an expectorant that helps thin and loosen mucus, making coughs more productive.
Market Size and Growth
The expectorant drugs market, which includes products like QC MUCUS RELIEF ER, is projected to experience significant growth. By 2024, the expectorant drugs market is estimated to reach USD 100 million and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% to reach USD 120 million by 2029[3].
Global Demand and Regional Insights
The demand for expectorant drugs has been driven by the rise in respiratory illnesses, including those associated with COVID-19. The Asia Pacific region is expected to be the fastest-growing market for expectorants, while North America holds the largest market share[3].
Product Specifics and Benefits
QC MUCUS RELIEF ER tablets, available in 600 mg and 1200 mg strengths, offer extended-release relief that lasts up to 12 hours. This product is comparable to Mucinex in terms of active ingredients and is designed for adults and children 12 years of age and older. It is gluten-free and provides quick and long-lasting relief from chest congestion and mucus[2].
Price Trends
As of the latest data, the prices for QC MUCUS RELIEF ER tablets vary slightly depending on the dosage and packaging. For example, the 600 mg tablets were priced around $0.345 to $0.399 per unit, while the 1200 mg tablets were priced around $0.472 to $0.476 per unit[1].
Market Drivers
Several factors are driving the growth of the expectorant drugs market, including:
- Increased Respiratory Illnesses: The rise in respiratory conditions such as influenza and post-COVID-19 complications like lung fibrosis and chronic obstructive pulmonary disease (COPD) has increased the demand for expectorants[3].
- Regulatory Changes: Changes in regulations, such as the reformulation of products containing pseudoephedrine due to its use in illicit drug synthesis, have shifted consumer preferences towards guaifenesin-based products[4].
Competitive Landscape
The expectorant drugs market is moderately concentrated, with key players including Merck KGaA, Perrigo Company plc, Sun Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, and Sanofi. These companies are continuously innovating and expanding their product lines to meet the growing demand for effective expectorants[3].
Challenges and Opportunities
- Supply Chain Strains: The increased demand for expectorants can strain supply chains, leading to potential shortages. However, this also presents an opportunity for manufacturers to scale up production and meet the growing demand[3].
- Regulatory Compliance: Ensuring compliance with evolving regulatory requirements, such as those related to the use of codeine in children, is crucial for maintaining market presence[4].
Consumer Preferences and Satisfaction
Consumers are increasingly looking for reliable and affordable options for managing respiratory symptoms. Products like QC MUCUS RELIEF ER, which offer long-lasting relief and are gluten-free, are well-received by consumers. The satisfaction guarantee and quality assurance from brands like Up&Up further enhance consumer trust[2].
Future Outlook
Given the projected growth of the expectorant drugs market, QC MUCUS RELIEF ER is likely to see continued demand. The product's extended-release formulation and comparison to well-known brands like Mucinex position it well in the market.
"The Expectorant Drugs Market size is estimated at USD 100 million in 2024, and is expected to reach USD 120 million by 2029, growing at a CAGR of 4.5% during the forecast period (2024-2029)"[3].
Key Statistics
- Market Size: Expected to reach USD 120 million by 2029[3].
- CAGR: 4.5% from 2024 to 2029[3].
- Fastest Growing Region: Asia Pacific[3].
- Largest Market: North America[3].
Key Takeaways
- The expectorant drugs market, including QC MUCUS RELIEF ER, is expected to grow significantly due to increased respiratory illnesses.
- QC MUCUS RELIEF ER offers extended-release relief and is comparable to Mucinex.
- The product is well-positioned in the market with its gluten-free formulation and satisfaction guarantee.
- Regulatory compliance and supply chain management are crucial for market success.
FAQs
Q: What is the expected market size of the expectorant drugs market by 2029? A: The expectorant drugs market is expected to reach USD 120 million by 2029[3].
Q: What is the CAGR of the expectorant drugs market from 2024 to 2029? A: The CAGR is expected to be 4.5% from 2024 to 2029[3].
Q: Which region is the fastest-growing market for expectorants? A: The Asia Pacific region is the fastest-growing market for expectorants[3].
Q: What are the key benefits of QC MUCUS RELIEF ER? A: QC MUCUS RELIEF ER provides extended-release relief lasting up to 12 hours, is gluten-free, and is designed for adults and children 12 years of age and older[2].
Q: How does QC MUCUS RELIEF ER compare to other products in the market? A: QC MUCUS RELIEF ER is comparable to Mucinex in terms of its active ingredient, guaifenesin, and offers similar benefits[2].
Cited Sources
- DrugPatentWatch - Drug prices and trends for QC MUCUS RELIEF ER.
- Target - Mucus Relief Extended Release Tablets - 20ct - Up&up.
- Mordor Intelligence - Expectorant Drugs Market Size & Share Analysis.
- HHS Texas - Cough and Cold Therapeutic Class Review (TCR).
More… ↓
